Akers Biosciences Announces Q2 2017 Earnings
Commercial & Investment Banking, Picture Gallery Tuesday, August 15th, 2017
Total Revenues for Q2 Up 25%
Total Revenues for Q2 Up 25%
Experienced directors with medical device and financial backgrounds to steer the Company through next phase of growth
Second Quarter Revenues Up 25% over Q2 2016
THOROFARE, NJ — (Marketwired) — 03/30/17 — Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces a private placement to raise approximately $2 million. Akers Bio will use the proceeds from the transaction as growth capital and for general corporate purposes.Akers Bio will issue 1,448,400 shares at a price of $1.40 per share, resulting in gross proceeds to the Company of $2,027,7
Sales of Flagship Rapid HIT Test +85% over 2015
THOROFARE, NJ — (Marketwired) — 01/13/17 — Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, today announces the closing of its previously announced underwritten public offering of 1,667,000 shares of common stock at a public offering price of $1.20 per share together with the issuance of 833,500 five-year warrants to purchase common stock with an exercise price of $1.50. In addition, t
THOROFARE, NJ — (Marketwired) — 01/09/17 — Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, today announces the entry into an agreement relating to the sale of 1,667,000 shares of common stock at a public offering price of $1.20 per share together with the issuance of 833,500 five-year warrants to purchase common stock with an exercise price of $1.50. The gross proceeds from the offe
THOROFARE, NJ — (Marketwired) — 12/22/16 — Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, reported on December 19, 2016 that the Company has signed a three-year agreement with the Greater New York Hospital Association (GNYHA) to introduce the Company–s flagship rapid tests for heparin-induced thrombocytopenia across GNYHA–s network of over 300 member hospitals and health systems.
© 2021 88Finance. All Rights Reserved. Log in
- Copyright by LayerMedia